The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia
Abstract
Background Aberrant N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic transmission has been implicated in schizophrenia. We studied whether transient inhibition of NMDA receptor activity during early postnatal development would produce a behavioral phenotype resembling that of individuals who are susceptible to develop schizophrenia.Methods Rat pups were given injections of the NMDA channel blocker MK801 on postnatal days 7 through 10. This period is akin to the prenatal second trimester of primate development. Cognitive function was tested in adulthood.Results Treatment with MK801 impaired cognitive flexibility and working memory. The impairment in cognitive flexibility was due to increased perseverative behavior. Treatment did not affect locomotor activity or recognition memory.Conclusions These results suggest that a brief disruption of NMDA receptors during a sensitive period of cortical development is sufficient to produce selective cognitive deficits that are relevant to schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A milder antagonism regime caused long-lasting behavioural changes and a specific longlasting decrease in cortical PVI numbers 29 , mimicking a key pathological feature of schizophrenia 2 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [29]
In the citing paper
“NMDAR antagonism likely induces a hyperglutamatergic state by reducing the activity of cortical interneurons, which particularly rely on NMDARs for their excitatory drive early in development 29,79 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [29]
In the citing paper
“Moreover, and as a result, PVI function itself might be permanently impaired as a result of relatively mild transient NMDAR hypofunction in the developing mouse that does not induce neuronal death 29,80 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [29]
In the citing paper
“The mechanism underlying this proposed loss of PVI phenotype involves cortical disinhibition leading to neuronal IL-6 production and consequent activation of NADPH oxidase, which generates H 2 O 2 29 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [29]
Citations
Cites
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Gazzaniga, M. S., & Bizzi, E. (2000) · Cited by 2,547
Effects of Different Brain Lesions on Card Sorting: The Role of the Frontal Lobes
MILNER, B. (1963) · Archives of Neurology · doi:10.1001/archneur.1963.00460070100010 · Cited by 2,217
Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., Tenkova, T. I., Stefovska, V., Turski, L., & Olney, J. W. (1999) · Science · doi:10.1126/science.283.5398.70 · Cited by 2,055
Translating developmental time across mammalian species
Clancy, B., Darlington, R. B., & Finlay, B. L. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00171-3 · Cited by 1,221
Genes for schizophrenia? Recent findings and their pathophysiological implications
Harrison, P. J., & Owen, M. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12379-3 · Cited by 597
Glutamatergic mechanisms in schizophrenia
Tsai, G., & Coyle, J. T. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.082701.160735 · Cited by 577
Bringing Order to the Glutamate Chaos in Schizophrenia
Moghaddam, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00757-8 · Cited by 403
Self-citation
Cited by
Sorted by citations
Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
Stephan, K. E., Friston, K. J., & Frith, C. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn176 · Cited by 1,134
Animal models of schizophrenia
Jones, C., Watson, D., & Fone, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01386.x · Cited by 771
Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase
Behrens, M. M., Ali, S. S., Dao, D. N., Lucero, J., Shekhtman, G., Quick, K. L., & Dugan, L. L. (2007) · Science · doi:10.1126/science.1148045 · Cited by 585
Camargo, L. M., Collura, V, Rain, J.-C., Mizuguchi, K., Hermjakob, H., Kerrien, S., Bonnert, T. P., Whiting, P. J., & Brandon, N. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001880 · Cited by 405
Epidemiology-driven neurodevelopmental animal models of schizophrenia
Meyer, U., & Feldon, J. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.10.018 · Cited by 378
Miller, O. H., Yang, L., Wang, C.-C., Hargroder, E. A., Zhang, Y., Delpire, E., & Hall, B. J. (2014) · eLife · doi:10.7554/elife.03581 · Cited by 358
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors
Bubeníková‐Valešová, V., Horáček, J., Vrajová, M., & Höschl, C. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.012 · Cited by 346
Autoantibodies in neurological disease
Prüß, H. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00543-w · Cited by 335
Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis
Hardingham, G. E., & Do, K. Q. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.19 · Cited by 304
Neural circuits subserving behavioral flexibility and their relevance to schizophrenia
Floresco, S. B., Zhang, Y., & Enomoto, T. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.001 · Cited by 298
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
A Critical Role for GluN2B-Containing NMDA Receptors in Cortical Development and Function
Wang, C.-C., Held, R. G., Chang, S.-C., Yang, L., Delpire, E., Ghosh, A., & Hall, B. J. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.023 · Cited by 180
Powell, S. B., Sejnowski, T. J., & Behrens, M. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.049 · Cited by 164
Behrens, M. M., & B, T. J. S. A. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.06.002 · Cited by 163
Kocsis, B. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.10.002 · Cited by 159
Glutamate signaling in the pathophysiology and therapy of schizophrenia
Lin, C., Lane, H., & Tsai, G. E. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.023 · Cited by 154
Stefani, M. R., & Moghaddam, B. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1656-06.2006 · Cited by 149
Self-citationSteeds, H., Carhart-Harris, R. L., & Stone, J. M. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314557797 · Cited by 143
Cuénod, M., Steullet, P., Cabungcal, J.-H., Dwir, D., Khadimallah, I., Klauser, P., Conus, P., & Kim, Q. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01374-w · Cited by 134
NR2B Signaling Regulates the Development of Synaptic AMPA Receptor Current
Hall, B. J., Ripley, B. A., & Ghosh, A. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3793-07.2007 · Cited by 130
Lanté, F., Meunier, J., Guiramand, J., De Jesus Ferreira, M., Cambonie, G., Aimar, R., Cohen‐Solal, C., Maurice, T., Vignes, M., & Barbanel, G. (2008) · Hippocampus · doi:10.1002/hipo.20421 · Cited by 124
Kittelberger, K. A., Hur, E. E., Sazegar, S., Keshavan, V., & Kocsis, B. (2011) · Brain Structure and Function · doi:10.1007/s00429-011-0351-8 · Cited by 122
Sex Differences in Psychiatric Disease: A Focus on the Glutamate System
Wickens, M. M., Bangasser, D. A., & Briand, L. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00197 · Cited by 117
Predicting Drug Efficacy for Cognitive Deficits in Schizophrenia
Hagan, J. J. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi058 · Cited by 111
Bondi, C. O., Taha, A. Y., Tock, J., Totah, N. K. B., Cheon, Y., Torres, G. E., Rapoport, S. I., & Moghaddam, B. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.06.007 · Cited by 117
Self-citationEarly brain development disruption from NMDA receptor hypofunction: Relevance to schizophrenia
du Bois, T. M., & Huang, X. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.09.001 · Cited by 106
Cabungcal, J.-H., Nicolas, D., Kraftsik, R., Cuénod, M., Do, K. Q., & Hornung, J.-P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.01.003 · Cited by 96
Elevated kynurenine pathway metabolism during neurodevelopment: Implications for brain and behavior
Notarangelo, F. M., & Pocivavsek, A. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.001 · Cited by 97
Kocsis, B., Brown, R. E., McCarley, R. W., & Hajós, M. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12081 · Cited by 96
Critchlow, H., Maycox, P. R., Skepper, J. N., & Krylova, O. Y. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2006.05.007 · Cited by 93
Thomases, D. R., Cass, D. K., & Tseng, K. Y. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.4147-12.2013 · Cited by 89
Jeevakumar, V., Driskill, C., Paine, A., Sobhanian, M., Vakil, H., Morris, B., Ramos, J., & Kroener, S. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.01.010 · Cited by 84
Models of Neurodevelopmental Abnormalities in Schizophrenia
Powell, S. B. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_57 · Cited by 87
Cabungcal, J.-H., Preissmann, D., Delseth, C., Cuénod, M., Kim, Q., & Schenk, F. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.03.001 · Cited by 83
Viggiano, D. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.06.033 · Cited by 82
Hsu, R., Woodroffe, A., Lai, W., Cook, M. N., Mukai, J., Dunning, J. P., Swanson, D. J., Roos, J. L., Abecasis, G. R., Karayiorgou, M., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001234 · Cited by 76
Lim, A. L., TAYLOR, D. A. H. B., & Malone, D. T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.10.052 · Cited by 74
Brain Rhythms Connect Impaired Inhibition to Altered Cognition in Schizophrenia
Pittman-Polletta, B., Kocsis, B., Vijayan, S., Whittington, M. A., & Kopell, N. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.005 · Cited by 80
Human gestational N‐methyl‐d‐aspartate receptor autoantibodies impair neonatal murine brain function
Jurek, B., Chayka, M., Kreye, J., Lang, K., Kraus, L., Fidzinski, P., Kornau, H.-C., Dao, L.-M., Wenke, N., Long, M., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25552 · Cited by 59
Xi, D., Keeler, B. E., Zhang, W., Houlé, J. D., & Gao, W. (2008) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2008.09.013 · Cited by 69
Li, J., Su, Y., Guo, C., Feng, Y., Yang, Y., Huang, R.-H., & Si, T. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.074 · Cited by 64
He, H., Mahnke, A. H., Doyle, S., Fan, N., Wang, C.-C., Hall, B. J., Tang, Y., Inglis, F. M., Chen, C., & Erickson, J. D. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.4505-11.2012 · Cited by 67
A Role for SERCA Pumps in the Neurobiology of Neuropsychiatric and Neurodegenerative Disorders
Britzolaki, A., Saurine, J., Klocke, B., & Pitychoutis, P. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12457-1_6 · Cited by 63
Yang, Y., Li, Y., Wang, W., Wan, J.-G., Yu, B., Mei-zhen, W., & Hu, B. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.03.013 · Cited by 60
Huang, X., Yang, J., Yang, S., Cao, S., Qin, D., Zhou, Y., Li, X., Ye, Y., & Wu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.22170 · Cited by 62
NMDA neurotransmission as a critical mediator of borderline personality disorder
Grosjean, B., & Tsai, G. E. (2007) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0710 · Cited by 57
Lim, A. L., TAYLOR, D. A. H. B., & Malone, D. T. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111430751 · Cited by 54
Long-term effects of neonatal MK-801 treatment on prepulse inhibition in young adult rats
Uehara, T., Sumiyoshi, T., Seo, T., Itoh, H., Matsuoka, T., Suzuki, M., & Kurachi, M. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1527-2 · Cited by 54
Uehara, T., Sumiyoshi, T., Seo, T., Matsuoka, T., Itoh, H., Suzuki, M., & Kurachi, M. (2010) · Brain Research · doi:10.1016/j.brainres.2010.07.013 · Cited by 53
Stojković, T., Radonjić, N. V., Velimirović, M., Jevtić, G., POPOVIC, V. M., Doknić, M., & Petronijević, N. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.013 · Cited by 53
Clifton, N. E., Morisot, N., Girardon, S., Millan, M. J., & Loiseau, F. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2845-3 · Cited by 57
Hong-luan, Y., Li, Q., Wang, D., Shi, L., Lü, G., Sun, L., Wang, L., Zhu, W. H., Mak, Y. T., Wong, N.-K., et al. (2011) · NeuroToxicology · doi:10.1016/j.neuro.2011.11.001 · Cited by 52
Gilabert‐Juan, J., Bellés, M., Sáez-Ibáñez, A. R., Carceller, H., Zamarbide-Forés, S., Moltó, M. D., & Nácher, J. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.07.008 · Cited by 56
Bonaventure, P., Aluisio, L. E., Shoblock, J. R., Boggs, J. D., Fraser, I. C., Lord, B., Lovenberg, T. W., & Galici, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020210 · Cited by 51
Janus, A., Lustyk, K., & Pytka, K. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06454-z · Cited by 50
du Bois, T. M., Deng, C., Han, M., Newell, K. A., & Huang, X. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.12.002 · Cited by 50
Watson, D. J., & Stanton, M. E. (2009) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2009.02.005 · Cited by 49
Geddes, A. E., Huang, X., & Newell, K. A. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.02.017 · Cited by 52
The Role of Caspase-3 Activation in Phencyclidine-Induced Neuronal Death in Postnatal Rats
Wang, C. Z., & Johnson, K. M. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301202 · Cited by 48
Wang, X., Pinto-Duarte, A., Sejnowski, T. J., & Behrens, M. M. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4907 · Cited by 46
Nozari, M., Shabani, M., Hadadi, M., & Atapour, N. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3580-8 · Cited by 45
Wędzony, K., Fijał, K., Maćkowiak, M., Chocyk, A., & Zajaczkowski, W. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.03.016 · Cited by 45
Kargieman, L., Riga, M. S., Artigas, F., & Celada, P. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.249 · Cited by 45
Millan, M. J., & Brocco, M. (2008) · Therapies · doi:10.2515/therapie:2008041 · Cited by 44
Coleman, L. G., Jarskog, L. F., Moy, S. S., & Crews, F. T. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.04.017 · Cited by 43
Persistent changes in learning and memory in rats following neonatal treatment with domoic acid
Adams, A. L., Doucette, T. A., James, R., & Ryan, C. L. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.11.019 · Cited by 43
Phensy, A. J., Duzdabanian, H. E., Brewer, S. M., Panjabi, A., Driskill, C. M., Berz, A., Peng, G., & Kroener, S. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00106 · Cited by 45
Kawabe, K., Iwasaki, T., & Ichitani, Y. (2007) · Brain Research · doi:10.1016/j.brainres.2007.06.062 · Cited by 42
Kékesi, G., Petrovszki, Z., Benedek, G., & Horváth, G. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.02.015 · Cited by 41
Chang, C.-H., Lane, H., Tseng, P., Chen, S.-J., Liu, C., & Lin, C. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118822157 · Cited by 42
Perinatal administration of PCP alters adult behaviour in female Sprague–Dawley rats
Dubois, T. B. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.11.017 · Cited by 40
Bortz, D. M., Wu, H., Schwarcz, R. M., & Bruno, J. P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.023 · Cited by 40
Perinatal phencyclidine treatment alters neuregulin 1/erbB4 expression and activation in later life
du Bois, T. M., Newell, K. A., & Huang, X. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.09.002 · Cited by 39
Li, J.-T., Zhao, Y., Wang, H.-L., Wang, X.-D., Su, Y., & Si, T. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.09.003 · Cited by 37
Behavioral Animal Models of Antipsychotic Drug Actions
Peleg‐Raibstein, D., Feldon, J., & Meyer, U. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_14 · Cited by 39
Shepard, R. M., Heslin, K. A., Hagerdorn, P. L., & Coutellier, L. D. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0436-3 · Cited by 39
Baier, P. C., Blume, A., Koch, J. M., Marx, A., Fritzer, G., Aldenhoff, J. B., & Schiffelholz, T. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.018 · Cited by 33
Su, Y., Huang, R.-H., Wang, X., Li, J., & Si, T. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.007 · Cited by 33
Elsworth, J. D., Groman, S. M., Jentsch, J. D., Valles, R., Shahid, M., Wong, E. H. F., Marston, H. M., & Roth, R. H. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.026 · Cited by 33
Uttl, L., Petrásek, T., Sengül, H., Svojanovská, M., Lobellová, V., Valeš, K., Radostová, D., Tsenov, G., Kubová, H., Mikulecká, A., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00042 · Cited by 31
Dyck, B. A., Guest, K. A., Sookram, C. D., Basu, D., Johnson, R. L., & Mishra, R. K. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.09.025 · Cited by 34
Synapse-specific contributions in the cortical pathology of schizophrenia
Seshadri, S., Zeledón, M., & Sawa, A. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.01.009 · Cited by 32
Borella, V., Seeman, M. V., Cordeiro, R. C., Santos, J. V. D., de Souza, M. R. M., Fernandes, E. N. D. S., Monte, A. S., Vasconcelos, S. M. M., Quinn, J. P., de Lucena, D. F., et al. (2015) · Developmental Neurobiology · doi:10.1002/dneu.22329 · Cited by 33
Distinct effects of ketamine and acetyl l-carnitine on the dopamine system in zebrafish
Robinson, B. L., Dumas, M., Cuevas, E., Gu, Q., Paule, M. G., Ali, S. F., & Kanungo, J. (2016) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2016.02.004 · Cited by 32
Brown, J. M., Hunihan, L. W., Prack, M. M., Harden, D., Bronson, J. J., Dzierba, C. D., Gentles, R. G., Hendricson, A. W., Krause, R., Macor, J. E., et al. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12618 · Cited by 30
NMDA receptor subtypes: Structure, function and therapeutics
Chaffey, H., & Chazot, P. L. (2008) · Current Anaesthesia and Critical Care · doi:10.1016/j.cacc.2008.05.004 · Cited by 31
Akıllıoğlu, K., Binokay, S., & Kocahan, S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.04.041 · Cited by 27
Xue, X., Shao, S., Wang, W., & Shao, F. (2013) · Neuropsychobiology · doi:10.1159/000356188 · Cited by 26
Faatehi, M., Basiri, M., Nezhadi, A., Shabani, M., Masoumi‐Ardakani, Y., Soltani, Z., & Nozari, M. (2019) · Brain Research · doi:10.1016/j.brainres.2019.01.023 · Cited by 25
Pérez, M. Á., Morales, C., Santander, O., García, F., Gómez, I., Peñaloza‐Sancho, V., Fuentealba, P., Dagnino‐Subiabre, A., Moya, P. R., & Fuenzalida, M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00372 · Cited by 24
Sex-specific restoration of MK-801-induced sensorimotor gating deficit by environmental enrichment
Nozari, M., Shabani, M., Farhangi, A. M., Mazhari, S., & Atapour, N. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.04.050 · Cited by 25
Uehara, T., Sumiyoshi, T., Hattori, H., Itoh, H., Matsuoka, T., Iwakami, N., Suzuki, M., & Kurachi, M. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.01.022 · Cited by 24
Akıllıoğlu, K., Melik, E. B., Melik, E., & Kocahan, S. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.06.006 · Cited by 24
Nozari, M., Mansouri, F. A., Shabani, M., Nozari, H., & Atapour, N. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3890-5 · Cited by 23
Furuie, H., Yamada, K., & Ichitani, Y. (2013) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000003 · Cited by 22
Effects of neonatal repeated MK-801 treatment on delayed nonmatching-to-position responses in rats
Kawabe, K., & Miyamoto, E. (2008) · Neuroreport · doi:10.1097/wnr.0b013e328302ee31 · Cited by 22
Lisek, M., Boczek, T., Ferenc, B., & Żylińska, L. (2015) · Cell and Tissue Research · doi:10.1007/s00441-015-2332-3 · Cited by 21
Zhao, Y., Li, J., Wang, X., Li, Y.-H., Huang, R.-H., Su, Y., & Si, T. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113497613 · Cited by 19
Kocahan, S., Akıllıoğlu, K., Binokay, S., Sencar, L., & Polat, S. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1008-1 · Cited by 19
Li, J., Feng, Y., Su, Y., Wang, X., & Si, T. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.04.008 · Cited by 19
Metadata
- Authors
- Stefani, M. R., & Moghaddam, B.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- Stefani, Mark Renato
- ORCID
- Moghaddam, Bita
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 57
- Issue
- 4
- Pages
- 433-436
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W1983202833
- Cited by
- 157
- References
- 32
- Citations by year
- 2026: 6 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 7 · 2020: 2 · 2019: 13 · 2018: 3 · 2017: 6 · 2016: 4 · 2015: 12 · 2014: 9 · 2013: 15 · 2012: 16
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (R21 MH65026, K02 MH01616, K02MH001616, R37MH048404, R37-MH48404, R21MH065026)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- NMDA receptor, MK-801, schizophrenia, cognitive flexibility, working memory, perseveration, glutamatergic neurotransmission, postnatal development, cortical development, cognitive impairment, rat model
- MeSH terms
- Age Factors, Animals, Animals, Newborn, Behavior, Animal, Cognition Disorders, Discrimination, Psychological, Exploratory Behavior, Locomotion, Male, Memory, Short-Term, Neuropsychological Tests, Psychomotor Performance, Schizophrenia, Receptors, N-Methyl-D-Aspartate, Dizocilpine Maleate, Rats, Sprague-Dawley, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review